These findings appear consistent with pre-clinical studies supporting a potentially synergistic approach to treating KRASMT pancreatic adenocarcinomas, through dual inhibition of c-RAF and EGFR16. The gene discussed is RAF1; the disease is pancreatic adenocarcinoma.